Literature DB >> 18712432

Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats.

Julienne E M Brouwers1, Bert van Rietbergen, Mary L Bouxsein.   

Abstract

An annual infusion of zoledronic acid (ZOL) reduces fracture risk in osteoporotic patients. Previously, we showed that a single ZOL injection inhibited changes in bone microstructure and strength in rat tibiae after ovariectomy. Here, we determined the effects of a single ZOL injection as preventive and restorative treatment on the bone microstructure and strength in lumbar and caudal vertebrae of ovariectomized (OVX) rats. Twenty-nine female 35-week-old Wistar rats were divided into four groups: SHAM-OVX (n = 9), OVX (n = 5), OVX and early ZOL (n = 8), and OVX and late ZOL (n = 7). ZOL was given once (20 microg/kg body weight s.c.) at OVX in the early ZOL group and 8 weeks later in the late ZOL group; rats were killed 16 weeks after OVX. Trabecular and cortical bone microarchitecture were measured in lumbar (L3) and caudal (Cd6) vertebrae using micro-computed tomography, and compressive mechanical properties were determined in L3 vertebrae. Compared to SHAM-OVX, OVX rats had significantly lower BV/TV; SMI, Tb.N, Tb.Sp, and Conn.D tended to be deteriorated in lumbar vertebrae, while both ZOL groups did not differ from the SHAM-OVX group. Both ZOL groups had significantly higher BV/TV than OVX; the early ZOL group also had significantly lower SMI and higher Tb.Th. OVX tended to decrease mechanical properties, while early and late ZOL treatment inhibited OVX-induced degeneration. Neither OVX nor ZOL induced changes in the trabecular microarchitecture of caudal vertebrae. In summary, in adult rats a single ZOL injection inhibited OVX-induced changes in lumbar vertebral bone microarchitecture and strength.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18712432     DOI: 10.1007/s00223-008-9160-3

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  4 in total

1.  Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.

Authors:  M R Allen; N X Chen; V H Gattone; X Chen; A J Carr; P LeBlanc; D Brown; S M Moe
Journal:  Osteoporos Int       Date:  2012-08-21       Impact factor: 4.507

2.  Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats.

Authors:  E Perilli; V Le; B Ma; P Salmon; K Reynolds; N L Fazzalari
Journal:  Osteoporos Int       Date:  2009-10-07       Impact factor: 4.507

3.  Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats.

Authors:  J E M Brouwers; M Ruchelsman; B v Rietbergen; M L Bouxsein
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

4.  The combination therapy with zoledronic Acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis.

Authors:  Deepak Kumar Khajuria; Rema Razdan; D Roy Mahapatra
Journal:  J Osteoporos       Date:  2014-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.